ArticleTherapeutics and clinical risk management2018

Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials.

Sooyoung Shin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.